QT Imaging Receives FDA Clearance for Enhanced Breast Acoustic CT Scanner
The US Food and Drug Administration (FDA) has granted 510(k) clearance to QT Imaging for an updated configuration of its Breast Acoustic CT scanner, a non-invasive medical imaging system designed for improved breast cancer detection. This advancement promises more comprehensive imaging, particularly of posterior breast tissue – an area often challenging to visualize with conventional methods. The updated scanner utilizes 3D ultrasound tomographic imaging, reconstructing images from both reflection-mode and transmission-mode ultrasound data, offering a potentially significant step forward in breast health assessment.
The Breast Acoustic CT scanner isn’t simply a refinement of existing technology. it represents a novel approach to breast imaging. Unlike traditional mammography, which relies on X-rays, or MRI, which can be costly and time-consuming, the QT Imaging system uses low-frequency sound waves. This approach aims to provide a more accessible, affordable, and patient-friendly option for breast screening and diagnostic imaging. The system’s ability to quantify fibroglandular tissue volume (FGV) and the ratio of fibroglandular tissue to total breast volume (TBV) provides clinicians with valuable data for risk assessment and monitoring, particularly important given the link between dense breast tissue and increased cancer risk.
Addressing the Challenges of Posterior Breast Tissue Imaging
One of the key improvements with this updated configuration lies in its ability to better visualize tissue located near the chest wall. According to QT Imaging, the new design incorporates a “tilted transmitter geometry” that expands imaging coverage. Bilal Malik, Ph.D., chief science officer of QT Imaging, explained that this modification “improves tomographic imaging coverage of breast tissue located near the chest wall, which is an area that can be extremely challenging to capture.” This is crucial as cancers in the posterior breast region can be more difficult to detect with standard imaging techniques, potentially leading to delayed diagnosis.
The challenge with posterior breast tissue stems from its location and the limitations of traditional imaging modalities. The chest wall presents a physical barrier, and dense tissue can obscure potential tumors. The updated scanner’s design aims to overcome these obstacles by optimizing the angle and range of the ultrasound waves, providing a more complete and detailed image of the entire breast. This enhanced coverage is expected to improve diagnostic accuracy and potentially reduce the number of false negatives.
How the Breast Acoustic CT Scanner Works
The Breast Acoustic CT scanner operates on the principle of tomographic imaging, similar to a CT scan but utilizing sound waves instead of X-rays. The system transmits low-frequency sound waves through the breast and measures how these waves are reflected and transmitted. This data is then processed using proprietary software to create a 3D reconstruction of the breast tissue. The resulting images provide a detailed view of the breast’s internal structure, allowing clinicians to identify potential abnormalities.
Beyond simply creating an image, the scanner’s software also performs quantitative analysis of the breast tissue. It calculates the volume of fibroglandular tissue (FGT) – the tissue type most associated with breast cancer risk – and expresses it as a percentage of the total breast volume. This information, known as the fibroglandular density (FGD), is increasingly recognized as an important factor in breast cancer risk assessment. According to the Cleveland Clinic, fibroglandular density describes how much of your breast tissue is considered fatty or dense, and is determined through mammograms. Higher FGD is associated with a greater risk of developing breast cancer and can also make it more difficult to detect tumors on mammograms.
The Significance of Fibroglandular Density
Understanding fibroglandular density is crucial for personalized breast cancer screening. Women with dense breasts may benefit from supplemental screening modalities, such as ultrasound or MRI, in addition to mammography. The Breast Acoustic CT scanner’s ability to accurately quantify FGD provides clinicians with valuable information to guide these decisions. By identifying women at higher risk, healthcare providers can tailor screening protocols to optimize early detection and improve outcomes.
The Cleveland Clinic explains that breasts with scattered fibroglandular tissue have slightly more dense tissue than fatty tissue. Dense tissue appears white on a mammogram, making it harder to detect cancerous tumors, which also appear white. Knowing a patient’s fibroglandular density is a critical component of a comprehensive breast health strategy.
QT Imaging’s Broader Strategy and Recent Partnerships
The FDA clearance for the updated Breast Acoustic CT scanner is part of QT Imaging’s broader strategy to advance medical imaging technology and improve global health outcomes. The company focuses on research, development, and commercialization of imaging systems utilizing low-frequency sound waves, aiming for solutions that are accessible, affordable, safe, and patient-focused. In January 2026, QT Imaging announced a partnership with Olea Medical to advance cloud-based breast imaging analytics.
This collaboration aims to integrate Olea Medical’s advanced visualization, quantitative analytics, and artificial intelligence (AI)-ready imaging technologies into QT Imaging’s Cloud SaaS Platform. The integration will support research workflows, quantitative imaging analysis, and clinical interpretation, potentially accelerating the development of new diagnostic tools and treatment strategies. By leveraging the power of AI and cloud computing, QT Imaging and Olea Medical are working to unlock the full potential of breast imaging data.
Looking Ahead: The Future of Breast Imaging
The FDA clearance of the updated Breast Acoustic CT scanner represents a significant milestone in the field of breast imaging. The technology’s ability to provide comprehensive 3D images, quantify fibroglandular density, and improve visualization of posterior breast tissue offers a promising new tool for clinicians. As the company continues to refine its technology and expand its partnerships, the Breast Acoustic CT scanner has the potential to play a vital role in improving breast cancer detection rates and ultimately saving lives.
The next step for QT Imaging will be the broader rollout of the updated scanner to clinical sites. The company is also expected to continue its research and development efforts, exploring new applications for its technology and further enhancing its diagnostic capabilities. The ongoing partnership with Olea Medical will likely yield further innovations in cloud-based breast imaging analytics, paving the way for more personalized and effective breast cancer screening and treatment.
Stay informed: For the latest updates on QT Imaging and the Breast Acoustic CT scanner, visit the company’s website at www.qtimaging.com. We encourage readers to share their thoughts and experiences with breast cancer screening in the comments below.
Worth a look